- recruitingPHASE3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
This study is looking into the long-term safety of a new medicine called dazodalibep for people with Sjögren's Syndrome. It involves individuals who have already taken part in previous studies of this medicine.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome.
This study is testing a new medicine, HZN-1116, for Sjögren's Syndrome. It wants to see if the medicine can make people feel better and improve their symptoms, while also checking if it's safe to use. Some people will get the real medicine, and others a dummy treatment.
Austria · Germany · Spain - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
This study is looking into a new treatment called Dazodalibep for Sjögren's Syndrome. It wants to see if the treatment helps reduce symptoms and if it's safe for people whose Sjögren's is causing moderate to severe problems in their body.
United States · Argentina · Australia - recruitingPHASE1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
This study is looking at a new medicine called CLN-978 for people with Sjögren's disease. It's an early-stage study to see how safe it is and how well it works. The medicine is given as an injection under the skin.
United States · France · Germany - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
This study is testing a new medicine, Deucravacitinib, for adults with an active form of Sjögren's Syndrome. Researchers want to see if it's safe and effective compared to a dummy pill. It's a key step to finding better treatments for this autoimmune condition.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
This study is looking at a new medicine called ianalumab for Sjögren's syndrome. We want to see how it affects cells in the salivary glands, how safe it is, and how the body uses it. This is an early-stage study.
France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Belgium · Czechia · Spain - authorisedTherapeutic exploratory (Phase II)
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
This study, called UPROOT, is looking into a new treatment for Sjögren's syndrome using a medicine called Gazyvaro. It aims to see if Gazyvaro can reduce certain immune cells in the blood and affected areas, which might help improve symptoms of Sjögren's syndrome.
Netherlands